The Future of AI-Driven CGM in Diabetes & Metabolic Health

https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/a2/d0/2e/a2d02e38-ee60-a2a4-bf5c-e6d951b93b39/mza_3048579604930026653.jpg/600x600bb.jpg

ATTD: Advanced Technologies and Treatments for Diabetes

ATTD on UNLOK

41 episodes

6 days ago

ATTD is the leading forum for the latest in diabetes research, technology, and clinical innovation. This podcast offers two types of content for healthcare professionals: * ATTD Conference Catch-up: AI-generated episodes with key insights from expert presentations & research discussions. * Curated Series: Human-led conversations such as CGM in Focus (supported by Dexcom), ATTD Tech Connect (sponsored by Medtronic), and previously Long-Acting Insulin Uncovered (supported by Eli Lilly and Company). Whether you're a specialist, researcher, or industry leader, hit subscribe.

Life Sciences

Science

RSS

All content for ATTD: Advanced Technologies and Treatments for Diabetes is the property of ATTD on UNLOK and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Life Sciences

Science

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_episode/43275051/43275051-1757347680364-cccee62f8fb46.jpg

The Future of AI-Driven CGM in Diabetes & Metabolic Health

ATTD: Advanced Technologies and Treatments for Diabetes

23 minutes 20 seconds

1 month ago

The Future of AI-Driven CGM in Diabetes & Metabolic Health

In this episode, Dr David Kerr continues his look at AI-driven CGM tools and the future of diabetes and metabolic health. He’s joined by Stanford W. Ascherman Professor of Genetics, Dr Michael Snyder to hear the latest on emerging technologies, and the shift towards integrative and personalised healthcare.

They discuss:

How AI and CGM technology is transforming diabetes and metabolic health management
AI identification of diabetes subtypes and personalised interventions
Impact of physical activity, sleep, and stress on glucose levels, as well as the emerging role of gut microbiome health in metabolic wellness
Potential of AI-driven tools for early intervention and improved health outcomes

Dr Snyder is the Stanford W. Ascherman Professor of Genetics and Director at the Stanford Center of Genomics and Personalized Medicine. He is a leader in the field of functional genomics and proteomics, and co-founder of many biotechnology companies, including Personalis, SensOmics, Qbio @qbioinc, January AI, Filtricine, Mirvie, and Protos.

Explore more on the ATTD Education Portal. Register now to access exclusive content and stay ahead in the field!

Make sure you’re subscribed to the ATTD Podcast feed today. Leave us a review and share with a colleague.